What’s the current market cap for GSK stock?

GSK (GSK) has a market cap of $102bn as of June 22, 2026.

What is the P/E ratio for GSK stock?

The price to earnings (P/E) ratio for GSK (GSK) stock is 26.96 as of June 22, 2026.

Does GSK stock pay dividends?

Yes, the GSK (GSK) stock pays dividends to shareholders. As of June 22, 2026, the dividend rate is $1.74545 and the yield is 3.71%. GSK has a payout ratio of 44.52% on a trailing twelve-month basis.

When is the next GSK dividend payment date?

The next GSK (GSK) dividend payment is scheduled for July 09, 2026.

What is the beta indicator for GSK?

GSK (GSK) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy GSK stock | $GSK Share Price

13:30

15:10

16:45

18:25

20:00

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

$GSK

Sector

Health

Primary listing

NYSE

Employees

66,841

Headquarters

London, United Kingdom

Website

www.gsk.com

GSK Metrics

BasicAdvanced

$102bn

26.96

$1.88

0.30

$1.75

3.71%

What the Analysts think about GSK

Analyst ratings (Buy, Hold, Sell) for GSK stock.

Bulls say / Bears say

Record Shingrix vaccine sales of £1.03 billion in Q1 exceeded expectations, underscoring robust demand for GSK’s flagship vaccine franchise. (Reuters)

Under CEO Luke Miels, GSK has diversified its pipeline through bolt-on acquisitions, agreeing to buy RAPT Therapeutics for $2.2 billion and 35Pharma for $950 million, strengthening its immunology and oncology offerings. (Reuters)

GSK shares jumped as much as 5.6% to a 25-year high after Miels outlined plans to accelerate R&D and target £40 billion in sales by 2031, reflecting renewed investor confidence. (Reuters)

Barclays estimated that one-off stocking of the new pre-filled Shingrix format contributed around £100 million of Q1 profit, creating risk of normalization in future quarters. (Reuters)

About half of the Q1 profit outperformance was driven by legal settlement provisions rather than core business operations, raising concerns over sustainable earnings quality. (Reuters)

Shares slid over 8% post-Q1 release as investors questioned the sustainability of results boosted by one-off factors, highlighting skepticism about GSK’s long-term growth narrative. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

GSK Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

GSK Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.